James Fierro, DO
Family Medicine · Wilmington, DENPI 1154345379
Payments from drug & device makers
Across 19 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$176
- Biohaven Pharmaceuticals, Inc.$109
- Lilly USA, LLC$108
- Biohaven Pharmaceutical Holding Company Ltd.$76
- Mallinckrodt Enterprises LLC$32
- Boston Scientific$23
- plus $29 from 2 others
What the payments were for
- Food & beverage$554100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 8 | $176 |
| Biohaven Pharmaceuticals, Inc. | 1 | $109 |
| Lilly USA, LLC | 5 | $108 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $76 |
| Mallinckrodt Enterprises LLC | 1 | $32 |
| Boston Scientific | 1 | $23 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$125
- NEXLETOL$125
- NURTEC ODT$109
How this compares
$554 in reported general payments places this provider in the 60th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 33 | $51,657 |
| Atorvastatin Calcium | 943 | $13,570 |
| Rosuvastatin Calcium | 480 | $11,755 |
| EliquisApixaban | 16 | $11,670 |
| Omeprazole | 438 | $7,364 |
| Levothyroxine Sodium | 581 | $5,810 |
| Ezetimibe | 120 | $5,649 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,907 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,535 |
| Amlodipine Besylate | 503 | $4,362 |
| Lisinopril | 448 | $4,117 |
| Valsartan | 83 | $3,603 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $3,493 |
| Esomeprazole Magnesium | 49 | $3,321 |
| SynthroidLevothyroxine Sodium | 115 | $3,301 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Wilmington
- David KrasnerWilmington$110K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Glenn HamiltonWilmington$17K
- Lakan Karlo MagatWilmington$16K
- Marc GrobmanWilmington$13K
- Julio NavarroWilmington$13K
- Anna MagatWilmington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.